Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc. (ORMP) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
ormp · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Oramed Pharmaceuticals Inc. (ORMP) measures how much investors pay for each dollar of the company's trailing earnings. ORMP's current PE ratio of 1.35x is calculated by dividing its stock price of $3.64 by its TTM earnings per share of $2.70. −85.6% discount vs 5Y avg 9.3x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Oramed Pharmaceuticals Inc.You ORMP | $149M | 1.35x | — | $2.70 |
 Clene Inc. CLNN | $55M | N/A | — | -$2.65 |
 Connect Biopharma Holdings Limited CNTB | $139M | N/A | — | -$1.00 |
 Context Therapeutics Inc. CNTX | $157M | N/A | — | -$0.38 |
 Coya Therapeutics, Inc. COYA | $83M | N/A | — | -$1.27 |
 InflaRx N.V. IFRX | $124M | N/A | — | -$0.68 |
 ImageneBio Inc IMA | $64M | N/A | — | -$9.31 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 1.84x | $1.55 | — | |
2024-12-31 FY2024 | — | $-0.47 | — | |
2023-12-31 FY2023 | 16.86x | $0.14 | — | |
2022-12-31 FY2022 | — | $-0.97 | — | |
2021-08-31 FY2021 | — | $-0.78 | — | |
2020-08-31 FY2020 | — | $-0.56 | — | |
2019-08-31 FY2019 | — | $-0.82 | — | |
2018-08-31 FY2018 | — | $-0.86 | — | |
2017-08-31 FY2017 | — | $-0.79 | — | |
2016-08-31 FY2016 | — | $-0.87 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Oramed Pharmaceuticals Inc. (ORMP) measures how much investors pay for each dollar of the company's trailing earnings. ORMP's current PE ratio of 1.35x is calculated by dividing its stock price of $3.64 by its TTM earnings per share of $2.70.
Frequently asked questions
ORMP pe ratio · 6 questionsORMP's current PE ratio is 1.35x as of 2026-06-09, based on a stock price of $3.64 and TTM EPS of $2.70. Data sourced from Financial Modeling Prep via ORMP's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Oramed Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09